Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parsaclisib - Incyte Corporation

Next Previous
Drug Profile

Parsaclisib - Incyte Corporation

Alternative Names: IBI-376; INCB-050465; INCB-50465

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Innovent Biologics; Mayo Clinic; National Cancer Institute (USA)
  • Class Antianaemics; Antihaemorrhagics; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Ketones; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Marginal zone B-cell lymphoma; Autoimmune haemolytic anaemia; Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Follicular lymphoma
  • Phase III Myelofibrosis
  • Phase II B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
  • No development reported Systemic lupus erythematosus
  • Discontinued Autoimmune haemolytic anaemia; Sjogren's syndrome

Most Recent Events

  • 02 Sep 2025 Peking Union Medical College Hospital plans an observational trial for Autoimmune hemolytic anaemiain unknown location in September 2025 (NCT07149818)
  • 28 May 2025 Pharmacokinetics and adverse events data from a phase I trial (In volunteers) presented at the 126th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2025)
  • 28 May 2025 Pharmacokinetics and adverse event data from a phase I trial in Hepatic Impairment presented at the 126th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top